Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
He brings over 30 years of experience across various organizations such as Asian Paints PPG, Berger Paints, Tata Steel, among others
The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The Group will continue to make proactive investments of its management resources in the life science business
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Subscribe To Our Newsletter & Stay Updated
